Polygenic prediction of coronary heart disease among 130 000 Mexican adults

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Aims: Most polygenic risk scores (PRSs) for coronary heart disease (CHD) are derived from European ancestry populations. This paper evaluates the performance of CHD PRSs in a Mexican population. Methods and results: 133 207 participants aged 35–79 years from the Mexico City Prospective Study were included. Eight PRSs (comprising 44–6 472 620 polymorphisms) were selected for prediction of CHD (defined as self-reported prior heart attack or angina, or CHD death before age 80 years). Logistic regression was adjusted for age, sex, and the first seven genetic principal components, before and after adjustment for other cardiovascular risk factors. The area under the receiving operating characteristic curve (‘C-statistic’) was also estimated. Of the included participants, 67% were women, the mean (±SD) age was 51 ± 12 years, and Indigenous American ancestry averaged 67%. CHD was documented for 5163 participants (3.9%), including 1901 prevalent and 3479 fatal cases. All eight PRSs were positively and log-linearly associated with CHD, with odds ratios (ORs) per 1 SD PRS increase ranging from 1.05 (95% CI, 1.03–1.08) to 1.29 (95% CI, 1.25–1.33). Associations were consistent across strata of age and ancestry and were independent of other vascular risk factors. For six PRSs, however, associations were substantially stronger in men than women. Multi-ancestry PRSs outperformed Eurocentric-ancestry PRSs. Despite remaining predictive of risk independently of established non-genetic risk factors, inclusion of a PRS into a risk model did not increase the C-statistic noticeably. Conclusion: In this Mexican population, existing PRSs predicted CHD independently of established vascular risk factors, particularly for men. PRSs better capturing genetic variation in Latin American people may further enhance risk prediction in such populations.
Funding Information
  • Mexican Health Ministry
  • National Council of Science and Technology for Mexico
  • Wellcome Trust (058299/Z/99)
  • Cancer Research UK
  • British Heart Foundation (RE/13/1/30181)
  • UK Medical Research Council (MC_UU_00017/2)
  • UK Medical Research Council (MR/Z504543/1)
  • National Autonomous University of Mexico
  • University of Oxford
  • Regeneron Pharmaceuticals
  • AstraZeneca (203141/Z/16/Z)

This publication has 41 references indexed in Scilit: